The FDA last month accepted the application for subcutaneous Leqembi for maintenance dosing, with a target action date of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical ...

ChatGPT-maker OpenAI unveiled a new logo, typeface (font), and color palette in a rebranding push. Although the changes are not very drastic, ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Inc. Regionals honors the fastest-growing privately held companies by region over a two-year period. These are emerging companies. Research shows these firms also tend to be the biggest job ...

The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...

Link Parks Inc. Dep. Pfd. (Rep. 1/1000th 5.25% Cum. Redeem. Pfd. Series X)-0.68% Link Parks Inc. Dep. Pfd. (Rep. 1/1000th Share 4.875% Pfd. Series Z) 0.08% Link Parks ...

Innovative Industrial Properties Inc. 9% Cum. Conv. Redeem. Pfd. Series A-0.39% Digital Realty Trust Inc. 5.25% Cum. Conv. Pfd. Series J-0.09% Digital Realty Trust Inc. 5.2% Cum. Redeem.